UK regulator debates whether AI scribes count as medical devices

UK regulators are examining whether AI-driven clinical documentation tools, often called AI scribes, should be classified as medical devices under current law.

The proposal has generated debate among industry groups, who warn that labeling these software solutions as devices could impose stricter approval requirements and affect market entry.

The newsletter also references other health-tech developments, including CMS’s removal of certain payment pathways for breakthrough devices and a Dexcom FDA pilot, but the primary focus is the AI scribe classification issue.

Observers note that the regulator’s decision could shape the development, deployment, and reimbursement of AI tools in the UK and may set a precedent for other jurisdictions.